» Articles » PMID: 20108112

Integrating the Multiple Dimensions of Genomic and Epigenomic Landscapes of Cancer

Overview
Specialty Oncology
Date 2010 Jan 29
PMID 20108112
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Advances in high-throughput, genome-wide profiling technologies have allowed for an unprecedented view of the cancer genome landscape. Specifically, high-density microarrays and sequencing-based strategies have been widely utilized to identify genetic (such as gene dosage, allelic status, and mutations in gene sequence) and epigenetic (such as DNA methylation, histone modification, and microRNA) aberrations in cancer. Although the application of these profiling technologies in unidimensional analyses has been instrumental in cancer gene discovery, genes affected by low-frequency events are often overlooked. The integrative approach of analyzing parallel dimensions has enabled the identification of (a) genes that are often disrupted by multiple mechanisms but at low frequencies by any one mechanism and (b) pathways that are often disrupted at multiple components but at low frequencies at individual components. These benefits of using an integrative approach illustrate the concept that the whole is greater than the sum of its parts. As efforts have now turned toward parallel and integrative multidimensional approaches for studying the cancer genome landscape in hopes of obtaining a more insightful understanding of the key genes and pathways driving cancer cells, this review describes key findings disseminating from such high-throughput, integrative analyses, including contributions to our understanding of causative genetic events in cancer cell biology.

Citing Articles

DNA methylation analysis in plants: review of computational tools and future perspectives.

Omony J, Nussbaumer T, Gutzat R Brief Bioinform. 2019; 21(3):906-918.

PMID: 31220217 PMC: 7612617. DOI: 10.1093/bib/bbz039.


High-Order Correlation Integration for Single-Cell or Bulk RNA-seq Data Analysis.

Tang H, Zeng T, Chen L Front Genet. 2019; 10:371.

PMID: 31080457 PMC: 6497731. DOI: 10.3389/fgene.2019.00371.


Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes.

Tokar T, Pastrello C, Ramnarine V, Zhu C, Craddock K, Pikor L Oncotarget. 2018; 9(10):9137-9155.

PMID: 29507679 PMC: 5823624. DOI: 10.18632/oncotarget.24070.


Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact.

Kuasne H, Barros-Filho M, Busso-Lopes A, Marchi F, Pinheiro M, Munoz J Oncotarget. 2017; 8(9):15294-15306.

PMID: 28122331 PMC: 5362487. DOI: 10.18632/oncotarget.14783.


Synthetic lethality in lung cancer and translation to clinical therapies.

Leung A, de Silva T, Bally M, Lockwood W Mol Cancer. 2016; 15(1):61.

PMID: 27686855 PMC: 5041331. DOI: 10.1186/s12943-016-0546-y.


References
1.
von Eschenbach A, Buetow K . Cancer informatics vision: caBIG. Cancer Inform. 2009; 2:22-4. PMC: 2675495. View

2.
Lin B, Wang J, Hong X, Yan X, Hwang D, Cho J . Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One. 2009; 4(8):e6589. PMC: 2720376. DOI: 10.1371/journal.pone.0006589. View

3.
Luo B, Cheung H, Subramanian A, Sharifnia T, Okamoto M, Yang X . Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008; 105(51):20380-5. PMC: 2629277. DOI: 10.1073/pnas.0810485105. View

4.
Rauch T, Zhong X, Wu X, Wang M, Kernstine K, Wang Z . High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A. 2007; 105(1):252-7. PMC: 2224196. DOI: 10.1073/pnas.0710735105. View

5.
Baudis M . Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer. 2007; 7:226. PMC: 2225423. DOI: 10.1186/1471-2407-7-226. View